1-5 of 5
Silvia Arcangeli
Close
Sort by
Journal Articles

Preclinical Assessment of Non-Virally Engineered CD33.CAR Cytokine-Induced Killer (CIK) Cells in Chemoresistant AML Patient-Derived Xenografts

Maria Caterina Rotiroti, PhD, Chiara Buracchi, PhD, Silvia Arcangeli, PhD, Chiara F Magnani, PhD, Claudia Cappuzzello, PhD, Zsuzsanna Izsvak, PhD, Stefania Galimberti, PhD, Maria Grazia Valsecchi, PhD, Giuseppe Dastoli, MD, Marta Serafini, PhD, Ettore Biagi, MD, Andrea Biondi, MD, Sarah Tettamanti, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2665.
https://doi.org/10.1182/blood-2019-130399
Published: 2019
Journal Articles

Specific Targeting of Acute Myeloid Leukemia By the Use of Non-Virally Engineered CIK (Cytokine-Induced Killer) Cells Expressing the Anti-CD33 Chimeric Antigen Receptor (CAR)

Maria Caterina Rotiroti, MSc, Silvia Arcangeli, PhD, Chiara Buracchi, PhD, Chiara Francesca Magnani, PhD, Claudia Cappuzzello, PhD, Ettore Biagi, MD, Sarah Tettamanti, PhD, Andrea Biondi, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2201.
https://doi.org/10.1182/blood-2018-99-114572
Published: 2018
Journal Articles

Balance of Anti-CD123 Chimeric Antigen Receptor (CAR) Binding Affinity and Density for the Treatment of Acute Myeloid Leukemia

Silvia Arcangeli, PhD, Marco Bardelli, PhD, Maria Caterina Rotiroti, Luca Simonelli, PhD, Chiara F. Magnani, PhD, Luca Varani, PhD, Andrea Biondi, MD, Ettore Biagi, MD, Sarah Tettamanti, PhD
Journal: Blood
Blood (2016) 128 (22): 2163.
https://doi.org/10.1182/blood.V128.22.2163.2163
Published: 2016
Journal Articles

Unraveling the Efficacy and Safety Profiles of Anti-CD123 Chimeric Antigen Receptors (CARs) in a Model of Acute Myeloid Leukemia Immunotherapy By Investigating CAR Binding Affinity and Density Variables

Silvia Arcangeli, Marco Bardelli, Sarah Tettamanti, Maria Caterina Rotiroti, Luca Simonelli, Chiara F Magnani, Luca Varani, Andrea Biondi, Prof, MD, Ettore Biagi, MD
Journal: Blood
Blood (2015) 126 (23): 1359.
https://doi.org/10.1182/blood.V126.23.1359.1359
Published: 2015
Journal Articles

Low-Dose Lenalidomide Improves CAR-Based Immunotherapy In CLL By Reverting T-Cell Defects In Vivo

Maria Teresa Sabrina Bertilaccio, Sarah Tettamanti, PhD, Greta Maria Paola Giordano Attianese, PhD, Giovanni Galletti, Silvia Arcangeli, Tania Veliz Rodriguez, Chiara Francesca Magnani, PhD, Federica Barbaglio, Lydia Scarfò, MD, Maurilio Ponzoni, MD, Andrea Biondi, MD, Federico Caligaris-Cappio, MD, Ettore Biagi, MD, PhD, Paolo Ghia, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 4171.
https://doi.org/10.1182/blood.V122.21.4171.4171
Published: 2013